Castlight Health Announces Third Quarter 2017 Results

Oct 25, 2017

Total Revenue of $34.6 million, Up 36% Year-over-Year

SAN FRANCISCO  October 25, 2017 – Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its third quarter ended September 30, 2017.

“We are encouraged by our second consecutive quarter of solid financial performance after closing the Jiff acquisition, with new business momentum, continued operating efficiencies and a broadening product footprint across our customer base,” said John Doyle, chief executive officer of Castlight Health. “With our comprehensive platform that simplifies healthcare navigation, we believe we help employers achieve more with their benefits spending and help their employees lead healthier, happier, and more productive lives.”

Financial performance for the three months ended September 30, 2017 compared to the three months ended September 30, 2016:

  • Total revenue of $34.6 million, an increase of 36%
  • Subscription revenue of $31.4 million, an increase of 31%
  • Gross margin of 62.3%, compared to 68.8%
  • Non-GAAP gross margin of 66.9% compared to 72.1%
  • Operating loss of $18.6 million, compared to a loss of $11.5 million
  • Non-GAAP operating loss of $6.6 million, compared to a loss of $5.5 million
  • Net loss per diluted share of $0.14, compared to a net loss per diluted share of $0.11
  • Non-GAAP net loss per diluted share of $0.05, compared to a net loss per diluted share of $0.05
  • Cash used in operations of $8.4 million, compared to $9.4 million used in operations

Total cash, cash equivalents and marketable securities was $87.1 million as of September 30, 2017.

The financial performance of Jiff, Inc., which Castlight acquired on April 3, 2017, is not included in the year-ago period metrics. A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Board of Directors Changes

Castlight Health today also announced changes to its board of directors. Castlight co-founder and executive chairperson Dr. Giovanni M. Colella and Jiff, Inc. co-founder Mr. James Currier, have stepped down from the Castlight board, effective today. Dr. Bryan Roberts, currently serving as lead independent director, assumed the chairperson role which he previously held from 2010 to April 2017. Additionally, Mr. Seth Cohen, an experienced senior sales leader at Castlight, will be joining the board, effective January 1, 2018.

“We would like to thank Gio and James for helping create two of the most revolutionary and successful companies in digital health that, combined, simplify healthcare for both employers and their employees. The board and the Castlight team are indebted to Gio and James for their vision, leadership and valuable contributions, and I would like to thank Gio personally for his mentorship over the years.” said John Doyle, chief executive officer of Castlight Health. “The board and I look forward to working with Seth, who brings a valuable, customer-centric perspective to our board that I believe will help us accelerate the adoption of our health navigation platform.”

“With Castlight’s increased focus on execution across its go-to-market, product integration and sustainability initiatives, James and I concluded it is the right time to step down from the board,” said Dr. Giovanni M. Colella. “We are incredibly proud of the Castlight family and believe the company, under its excellent leadership from John and Derek, is in a strong position to deliver on its strategy. James and I wish the entire Castlight team continued success.”

About Seth Cohen

A sales leader with the company since November 2010, Mr. Cohen is currently Castlight’s vice president, sales and alliances, and has extensive experience in digital healthcare go-to-market execution. Prior to joining Castlight, Mr. Cohen was a consultant for McKinsey & Company as a member of their healthcare payer and provider practice, and an adjudicator for the Beacon Community Grant program within the U.S. Department of Health and Human Services. Mr. Cohen holds a MBA from the Harvard Business School, an MPH from the Harvard Kennedy School, and a BA in International Relations from Stanford University.

Business Outlook

For the full year 2017, the Company expects GAAP revenue to be above $130 million. Based on operating expense synergies, Castlight expects to beat its previously-issued full year 2017 non-GAAP operating loss guidance range of $31 to $35 million. The company also expects to beat its previously-issued full year 2017 non-GAAP net loss per share guidance range of approximately $0.24 to $0.28, based on approximately 125 to 127 million shares. Non-GAAP guidance metrics exclude the effects of stock-based compensation, amortization of intangibles, capitalization and amortization of internal-use software, changes in fair value of contingent consideration, and charges related to the acquisition.

Quarterly Conference Call

Castlight Health senior management will host a conference call to discuss its third quarter 2017 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company’s Investor Relations website at An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (866) 393-4306. The conference ID number is 93260120. A replay will be available for one week at (855) 859-2056, passcode 93260120.

Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating loss and non-GAAP net loss exclude stock-based compensation, litigation settlement, charges related to a reduction in workforce, amortization of intangibles, capitalization and amortization of internal-use software, changes in fair value of contingent consideration and charges related to the acquisition and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2017 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense, capitalization and amortization of internal-use software, changes in fair value of contingent consideration and charges related to the acquisition, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software and charges related to the proposed acquisition for the year.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s 2017 full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2017 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

As of
30, 2017
31, 2016
Current assets:
Cash and cash equivalents$44,986$48,722
Marketable securities42,07465,882
Accounts receivable, net26,01714,806
Deferred commissions7,8058,218
Prepaid expenses and other current assets5,7123,382
Total current assets126,594141,010
Property and equipment, net5,6705,285
Restricted cash, non-current1,3251,144
Intangible assets, net21,469
Deferred commissions, non-current4,0215,050
Other assets7,3384,677
Total assets$258,202$157,166
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$3,393$2,288
Accrued expenses and other current liabilities14,6156,369
Accrued compensation12,1519,443
Deferred revenue34,97430,623
Total current liabilities65,13348,723
Deferred revenue, non-current8,4125,245
Debt, non-current5,423
Other liabilities, non-current1,9551,236
Total liabilities80,92355,204
Commitments and contingencies
Stockholders’ equity:
Class A and Class B common stock1310
Additional paid-in capital580,282457,596
Accumulated other comprehensive loss(5)
Accumulated deficit(403,011)(355,644)
Total stockholders’ equity177,279101,962
Total liabilities and stockholders’ equity$258,202$157,166
Three Months Ended
September 30,
Nine Months Ended
September 30,
Professional services and other3,2091,6347,4534,944
Total revenue, net34,57225,50194,41671,803
Cost of revenue:
Cost of subscription (1)8,1233,98820,07512,218
Cost of professional services and other (1)4,8983,97813,67913,941
Total cost of revenue13,0217,96633,75426,159
Gross profit21,55117,53560,66245,644
Operating expenses:
Sales and marketing (1)16,00613,14347,02444,877
Research and development (1)13,80910,57340,07430,619
General and administrative (1)10,3075,33826,07119,902
Total operating expenses40,12229,054113,16995,398
Operating loss(18,571)(11,519)(52,507)(49,754)
Other income, net84116288304
Loss before income tax benefit$(18,487)(11,403)$(52,219)(49,450)
Income tax benefit5,206
Net loss$(18,487)$(11,403)$(47,013)$(49,450)
Net loss per Class A and B share, basic and diluted$(0.14)$(0.11)$(0.38)$(0.50)
Weighted-average shares used to compute basic and diluted net loss per Class A and B share132,251103,147122,67599,734
(1)Includes stock-based compensation expense as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
Cost of revenue:
Cost of subscription$258$139$638$367
Cost of professional services and other3424561,4001,468
Sales and marketing3,1102,1907,7056,644
Research and development1,6311,6315,6754,300
General and administrative1,1211,2363,5863,476
Three Months EndedNine Months Ended
30, 2017
30, 2016
30, 2017
30, 2016
Operating activities:
Net loss$(18,487)$(11,403)$(47,013)$(49,450)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,8148224,5722,407
Stock-based compensation6,4635,65219,00416,255
Amortization of deferred commissions2,9501,0428,1203,157
Release of deferred tax valuation allowance due to business combination(5,206)
Change in fair value of contingent consideration liability3,9313,288
Accretion and amortization of marketable securities(64)10122406
Changes in operating assets and liabilities:
Accounts receivable(4,661)(3,397)(7,778)(3,137)
Deferred commissions(3,280)(1,479)(6,678)(4,403)
Prepaid expenses and other assets467745(393)(68)
Accounts payable909410401300
Accrued expenses and other liabilities3,148(3,583)2,623(4,046)
Deferred revenue(1,541)1,7335,6613,318
Net cash used in operating activities(8,351)(9,357)(23,377)(35,261)
Investing activities:
Restricted cash181(181)
Purchase of property and equipment(1,345)(345)(2,276)(1,587)
Purchase of marketable securities(25,077)(11,971)(56,852)(73,163)
Maturities of marketable securities16,89635,57080,633126,157
Business combination, net of cash acquired(2,264)
Net cash provided by (used in) investing activities(9,345)23,25419,06051,407
Financing activities:
Proceeds from the exercise of stock options4816361,3122,576
Proceeds from issuance of common stock and warrants17,358
Payments of issuance costs related to equity(76)(731)(122)
Net cash provided by financing activities48156058119,812
Net (decrease) increase in cash and cash equivalents(17,215)14,457(3,736)35,958
Cash and cash equivalents at beginning of period62,20140,65148,72219,150
Cash and cash equivalents at end of period$44,986$55,108$44,986$55,108
Non-cash investing and financing activity:
Non-cash purchase consideration related to acquisition of Jiff$$$101,692$
(In thousands, except per share data)
Three Months EndedNine Months Ended
June 30,September
Gross profit:
GAAP gross profit subscription$23,240$22,128$19,879$66,888$54,641
Stock-based compensation258253139638367
Amortization of internal-use software244244244732732
Amortization of intangibles7517511,502
Reduction in workforce5
Acquisition related costs5252
Non-GAAP gross profit subscription$24,493$23,428$20,262$69,812$55,745
GAAP gross margin subscription74.1%74.2%83.3%76.9%81.7%
Non-GAAP gross margin subscription78.1%78.5%84.9%80.3%83.4%
GAAP gross loss professional services$(1,689)$(2,528)$(2,344)$(6,226)$(8,997)
Stock-based compensation3425974561,4001,468
Reduction in workforce4103
Acquisition related costs(4)17160
Non-GAAP gross loss professional services$(1,351)$(1,914)$(1,884)$(4,666)$(7,426)
GAAP gross margin professional services(53)%(112)%(143)%(84)%(182)%
Non-GAAP gross margin professional services(42)%(85)%(115)%(63)%(150)%
GAAP gross profit$21,551$19,600$17,535$60,662$45,644
Impact of non-GAAP adjustments1,5911,9148434,4842,675
Non-GAAP gross profit$23,142$21,514$18,378$65,146$48,319
GAAP gross margin62.3%61.1%68.8%64.2%63.6%
Non-GAAP gross margin66.9%67.0%72.1%69.0%67.3%
Operating expense:
GAAP sales and marketing$16,006$16,575$13,143$47,024$44,877
Stock-based compensation(3,110)(2,441)(2,190)(7,705)(6,644)
Amortization of intangibles(448)(448)(896)
Reduction in workforce(48)(422)
Acquisition related costs14(518)(909)
Non-GAAP sales and marketing$12,462$13,168$10,905$37,514$37,811
GAAP research and development$13,809$15,194$10,573$40,074$30,619
Stock-based compensation(1,631)(2,254)(1,631)(5,675)(4,300)
Capitalization of internal-use software
Reduction in workforce(18)(136)
Acquisition related costs(126)(393)
Non-GAAP research and development$12,178$12,814$8,924$34,006$26,183
GAAP general and administrative$10,307$6,766$5,338$26,071$19,902
Stock-based compensation(1,121)(1,169)(1,236)(3,586)(3,476)
Litigation settlement(250)(2,876)
Amortization of intangibles(17)(17)(34)
Change in fair value of contingent consideration liability(3,931)643(3,288)
Reduction in workforce(10)(90)
Acquisition related costs(126)(899)(3,365)
Non-GAAP general and administrative$5,112$5,324$4,092$15,548$13,460
GAAP operating expense$40,122$38,535$29,054$113,169$95,398
Impact of non-GAAP adjustments(10,370)(7,229)(5,133)(26,101)(17,944)
Non-GAAP operating expense$29,752$31,306$23,921$87,068$77,454
Operating loss:
GAAP operating loss$(18,571)$(18,935)$(11,519)$(52,507)$(49,754)
Impact of non-GAAP adjustments11,9619,1435,97630,58520,619
Non-GAAP operating loss$(6,610)$(9,792)$(5,543)$(21,922)$(29,135)
Net loss and net loss per share:
GAAP net loss$(18,487)$(13,717)$(11,403)$(47,013)$(49,450)
Total pre-tax impact of non-GAAP adjustments11,9619,1435,97630,58520,619
Release of deferred tax valuation allowance due to business combination(5,206)(5,206)
Income tax impact of non-GAAP adjustments
Non-GAAP net loss$(6,526)$(9,780)$(5,427)$(21,634)$(28,831)
GAAP net loss per share, basic and diluted$(0.14)$(0.11)$(0.11)$(0.38)$(0.50)
Non-GAAP net loss per share, basic and diluted$(0.05)$(0.07)$(0.05)$(0.18)$(0.29)
Shares used in basic and diluted net loss per share computation132,251130,537103,147122,67599,734

Castlight Media Contact:
Shannon Magill
[email protected]

Castlight Investor Contact:
Gary J. Fuges, CFA
[email protected]

Press Information

[email protected]